文献速递皮肤肿瘤

转移性黑色素瘤患者接受免疫检查点抑制剂治疗后新发原发性皮肤黑色素瘤的发病率:单中心队列研究

Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
PubMed 文献 · JAMA Dermatol · 2021-01-01

该单中心回顾性队列研究纳入2251例接受伊匹木单抗、纳武利尤单抗和/或帕博利珠单抗治疗的转移性黑色素瘤患者,中位随访期间42例(1.9%)诊断48个新发原发性皮肤黑色素瘤,5年病因特异性累积风险为4.9%,提示ICI治疗后仍需警惕新发黑色素瘤。

要点

  • ICI治疗转移性黑色素瘤后新发皮肤黑色素瘤的总体发生比例为1.9%。
  • 新发黑色素瘤的发病率为1103例/10万人年,5年累积风险4.9%。

核心结论

  • 接受ICI治疗的转移性黑色素瘤患者仍存在新发原发性皮肤黑色素瘤的风险。

研究设计与样本

  • 单中心、回顾性、观察性队列研究,利用纽约一家三级癌症医院的机构数据库纳入2251例转移性黑色素瘤患者。
  • 暴露为伊匹木单抗、纳武利尤单抗和/或帕博利珠单抗治疗,主要结局为新发原发性皮肤黑色素瘤的发生比例、发病率和5年病因特异性累积风险。

主要发现

  • 2251例患者中42例(1.9%)在ICI开始后中位397.5天(范围39-2409天)诊断48个新发原发性皮肤黑色素瘤。
  • 大多数新发黑色素瘤(n=30,62.5%)在末次ICI给药后诊断。

关键数值与推荐

  • 新发皮肤黑色素瘤的总体发生比例为1.9%(95% CI,1.4%-2.5%)。
  • 发病率为1103例/10万人年(95% CI,815-1492)。
  • 5年病因特异性累积风险为4.9%(95% CI,3.3%-7.4%)。

临床怎么用

  • 对接受ICI治疗的转移性黑色素瘤患者,尤其是有黑色素瘤家族史者,应持续进行皮肤监测以早期发现新发原发性黑色素瘤。
  • 新发黑色素瘤多出现在ICI停药后,提示治疗结束后仍需长期随访。

局限性

  • 单中心回顾性观察性研究,结果外推需谨慎。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The development of new primary cutaneous melanoma (CM) after starting immune checkpoint inhibitor (ICI) therapy is poorly characterized. OBJECTIVE: To determine the incidence of new CM in patients treated with ipilimumab, nivolumab, and/or pembrolizumab for metastatic melanoma. DESIGN, SETTING, AND PARTICIPANTS: Single-center, retrospective, observational cohort study using an institutional database to identify patients diagnosed with melanoma at a tertiary care cancer hospital in New York, New York. EXPOSURES: Ipilimumab, nivolumab, and/or pembrolizumab treatment for metastatic melanoma. MAIN OUTCOMES AND MEASURES: Primary outcomes were the incidence proportion, the incidence rate, and the 5-year cause-specific cumulative risk. RESULTS: A total of 2251 patients were included in the study; mean (SD) age at the time of ICI start was 62.8 (14.4) years. The majority were male (63.8%, n = 1437), White (92.7%, n = 2086), and non-Hispanic (92.1%, n = 2073). Forty-two of 2251 patients who received ipilimumab, nivolumab, and/or pembrolizumab were diagnosed with 48 new CMs at a median (range) of 397.5 (39-2409) days after ICI initiation. The median age of affected patients at the time of ICI first dose was 66.5 years. The majority were male (66.7%, n = 28), White (92.9%, n = 39), and non-Hispanic (100.0%, n = 42). There were no differences in age, sex, race, and ethnicity among patients who did and did not develop a new CM. Patients who developed a new CM were more likely to have a family history of melanoma (23.8% vs 16.3%, P = .02). Most new CMs (n = 30, 62.5%) were diagnosed after the last date of ICI administration. Twenty-seven (56.3%) new CMs were in situ and 21 (43.8%) were invasive. Of the invasive CMs with a reported Breslow thickness (n = 20), the median (range) thickness was 0.4 (0.1-8.4) mm. The overall incidence proportion of new CM was 1.9% (95% CI, 1.4%-2.5%) and the incidence rate was 1103 cases per 100 000 person-years (95% CI, 815-1492). The 5-year cumulative cause-specific risk of new CM was 4.9% (95% CI, 3.3%-7.4%). CONCLUSIONS AND RELEVANCE: Patients treated with ICI therapy for metastatic melanoma remain at risk for the development of new CM.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Nanda JK, Dusza SW, Navarrete-Dechent C, et al. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study. JAMA Dermatol. 2021. PMID: 32936222. doi:10.1001/jamadermatol.2020.3671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。